STOCKHOLM (Reuters) – Danish biotech Bavarian Nordic said on Friday the order book for delivery of its vaccine for mpox and smallpox in 2025 currently totals around 2.40 billion crowns ($340 million), including previously announced deferred revenue.
The World Health Organisation in August declared mpox a global public health emergency for the second time in two years after a variant of the virus called clade Ib spread from the Democratic Republic of Congo to neighbouring countries.
Bavarian Nordic is one of few firms that makes vaccine for mpox, a viral infection that causes flu-like symptoms and pus-filled lesions, and while usually mild, it can kill.
“The committed orders for next year, combined with improved performance in our Travel Health business, and the launch of our chikungunya vaccine in Europe and the U.S. have set us up for another exciting and eventful year,” it said in a statement.
The company reported a small year-on-year drop in third-quarter sales but a swing to profit before interest and tax.
($1 = 7.0662 Danish crowns)
(Reporting by Anna Ringstrom, editing by Terje Solsvik)
